在阿尔茨海默氏症的朋友和敌人
Ernest K J Pauwels1, Gerard J Boer2
1Leiden University and Leiden University Medical Center, Leiden, The Netherlands.
概括
阿尔茨海默病涉及大脑炎症和病原体,新的治疗方法针对早期检测和根源原因,如陶. 在临床前阶段的早期干预为有效的阿尔茨海默病治疗提供了最好的机会.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,没有有效的治疗方法,以神经元损伤和亡为特征.
- 由激活的星细胞和微质细胞驱动的大脑炎症,有助于AD的发病,导致β-粉样蛋白和tau蛋白沉积.
- 诸如细菌 (Helicobacter pylori,克拉米迪亚肺炎, Porphyromonas gingivalis,Borrelia burgdorferi) 和病毒 (简单疹病毒1,细胞大脑病毒,爱斯坦-巴尔病毒) 等病原体都与引发AD中神经炎症有关.
研究的目的:
- 探索神经炎症和病原体在阿尔茨海默氏症病因学中的作用.
- 审查当前的治疗策略,包括针对β-粉样蛋白的基于抗体的方法.
- 突出早期检测的重要性和阿尔茨海默病的新疗法目标.
主要方法:
- 对有关阿尔茨海默氏症病原学的现有文献的审查,重点关注炎症过程和微生物参与.
- 分析当前和新兴的治疗策略,包括抗体治疗和早期检测生物标志物.
- 讨论AD连续性和针对临床前阶段的潜力.
主要成果:
- 目前的抗体治疗 (aducanumab,lecanemab,donanemab) 在阿尔茨海默病患者中表现出有限的成功.
- 早期检测生物标志物,如血神经纤维光链,对于临床前阶段的干预至关重要.
- 甲基氨酸基酸显示出防止陶纠形成的潜力,代表了根源原因治疗方法.
结论:
- 阿尔茨海默病的发病过程复杂,涉及神经炎症,特定的分子实体 (TREM2,SYK,C22,C33) 和传染病原体.
- 针对阿尔茨海默病的临床前阶段,以长期无症状期为特征,对于有效治疗至关重要.
- 新兴的疗法专注于早期检测和解决根源原因,如病理,为管理阿尔茨海默病提供了新的希望.
更多相关视频
06:27Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
9.3K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Dementia
131
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
131
Role of Neurotransmitters in Memory
611
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
611
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
